Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

17 treatments under study, led by Pro118 Ophthalmic Solution 0015

Research Leaders

8 sponsors active, led by Bausch & Lomb Incorporated

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 8 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (1)
Phase 2 (2)
Phase 3 (4)
Phase 4 (1)

Trial Status

Completed6
Unknown1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 6 completed trials

Clinical Trials (8)

Research Network

Common Treatments

  • Pro118 Ophthalmic Solution 00151
  • Olopatadine1
  • Azelastine Hcl Oph Solsimulating Epinastine Hcl Oph Soln1
  • Ketotifen Fumarate1
  • Olopatadine Hydrochloride1

Active Sponsors

  • Bausch & Lomb Incorporated2
  • Laboratoires Thea1
  • Novartis1
  • Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.1
  • Alcon Research1

Top Investigators

Related Conditions

  • Perennial Allergic Conjunctivitis1
  • Conjunctivitis Allergic1
  • Seasonal Allergic Rhinitis1
  • Ocular Allergy1
  • Ocular Itching1

Activity Timeline